Results 91 to 100 of about 259,590 (298)

Effectiveness of antiretroviral therapy in the single-tablet regimen era

open access: yesRevista de Saúde Pública, 2018
OBJECTIVE To evaluate the effectiveness of antiretroviral therapy and the associated factors according to the type of regimen used: Single Tablet Regimen or Multiple Tablet Regimen.
Juliana de Oliveira Costa   +5 more
doaj   +1 more source

Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. [PDF]

open access: yes, 2009
In high-income countries, viral load is routinely measured to detect failure of antiretroviral therapy (ART) and guide switching to second-line ART. Viral load monitoring is not generally available in resource-limited settings. We examined switching from
Boulle, A   +18 more
core   +4 more sources

Affinity Proteomics‐Based Non‐Invasive Detection of Clinically Significant Liver Disease

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Using UK Biobank proteomic data, we identified a five‐protein score reflecting hepatic stellate cell activation and hepatocellular injury that predicts major adverse liver outcomes and clinically significant fibrosis, with consistent performance validated in two independent cohorts (patients with HIV and alpha1‐antitrypsin deficiency).
Sriram Balasubramani   +14 more
wiley   +1 more source

Brain viral reservoir seeding and neurological metabolic dysregulation in early‐life immunodeficiency virus infection

open access: yesBrain Pathology, EarlyView.
Brain viral reservoirs were undetectable in neonatal SIV during the first 3 days post infection; antiretroviral therapy (ART) at 3 dpi prevented brain reservoir seeding and normalized metabolic function, highlighting the necessity of very early treatment to protect the developing CNS.
Li Ma   +12 more
wiley   +1 more source

Initiation of antiretroviral therapy

open access: yesIndian Journal of Sexually Transmitted Diseases and AIDS, 2014
With the widespread availability of antiretroviral therapy, there is a dramatic decline in HIV related morbidity and mortality in both developed and developing countries. Further, the current antiretroviral drug combinations are safer and the availability of newer monitoring assays and guidelines has vastly improved the patient management.
Pandhi, Deepika, Ailawadi, Pallavi
openaire   +3 more sources

How Much Does It Cost to Provide Antiretroviral Therapy for HIV/AIDS in Africa? [PDF]

open access: yes, 2010
Background: Many African countries are rapidly expanding HIV/AIDS treatment programs. Empirical information on the cost of delivering antiretroviral therapy (ART) for HIV/AIDS is needed for program planning and budgeting.
Long, Lawrence, Rosen, Sydney
core   +1 more source

HPV42 – a human papillomavirus classified as a low‐risk type with oncogenic potential

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Human papillomavirus (HPV) type 42 is a rare HPV type currently classified as “low‐risk” and belongs to the alpha genus. It has primarily been detected in benign vulvar papillomas and is predominantly associated with benign lesions such as anogenital warts.
Sven Niklas Burmann   +7 more
wiley   +1 more source

Retention on antiretroviral therapy in low- and middle-income countries: systematic review of papers and abstracts since 2008 [PDF]

open access: yes, 2013
This repository item contains a single issue of the Health and Development Discussion Papers, an informal working paper series that began publishing in 2002 by the Boston University Center for Global Health and Development.
Fox, Matthew, Rosen, Sydney
core   +1 more source

Benefit of viral load testing for confirmation of immunological failure in HIV patients treated in rural Malawi. [PDF]

open access: yes, 2011
Objective  Viral load testing is used in the HIV programme of Chiradzulu, Malawi, to confirm the diagnosis of immunological failure to prevent unnecessary switching to second-line therapy.
Badri   +14 more
core   +2 more sources

Home - About - Disclaimer - Privacy